Results 131 to 140 of about 15,674 (165)

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer. [PDF]

Cancers (Basel)
Guida C, Evangelista L, Spadafora M, Facchini G, Mansi L.   +4 more
europepmc   +1 more source

Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs. [PDF]

Prostate
Lothion-Roy J, Aeschlimann L, Hiller LA, Rottenberg S, Mongan NP, Rutland CS, Rakha E, Dean A, Rubin MA, de Brot S.   +9 more
europepmc   +1 more source

Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis. [PDF]

Jpn J Clin Oncol
Hata S, Suzuki S, Fujinami H, Yamanaka N, Shin T.   +4 more
europepmc   +1 more source

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy. [PDF]

EMBO Mol Med
Baurès M, Vieira Aleixo AS, Pacreau E, Koshy A, Friedrich V, Diedisheim M, Raigel M, Hua Y, Dariane C, Boutillon F, Kenner L, Marine JC, Laverny G, Metzger D, Rambow F, Guidotti JE, Goffin V.   +16 more
europepmc   +1 more source

[¹⁸F]PSMA-1007 PET/CT in biochemical recurrence after radical prostatectomy: A single-center experience of detection rate and lesion distribution. [PDF]

PLoS One
Wang Y, Feng L, He L, Liu N, Wang H.
europepmc   +1 more source

[Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients]. [PDF]

Pan Afr Med J
Sadaoui I, Sadaoui I, Joutei HAH, Benomar H, Nadifi S.   +4 more
europepmc   +1 more source

Therapeutic pressure drives the evolution of a protective ecotype characterized by AR-loss-induced senescence in prostate cancer. [PDF]

Theranostics
He L, Jiang J, Liu S, Song H, Lu T, Hu Z, Li Y, Zhu H, Zhou Y, Li Z, Yang F, Zhang K, Zhang R, Wu T, Gan K, Zhao B, Zhang J, Si D, Zhang R, Shi C, Wen W, Han D, Xu C, Qin W.   +23 more
europepmc   +1 more source

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. [PDF]

Signal Transduct Target Ther
Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG.   +18 more
europepmc   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report. [PDF]

Int Cancer Conf J
Terrano V, Perri E, Cioffo C, Mastroianni G, Palumbo MA, Ciardiello F, Troiani T, Napolitano S.   +7 more
europepmc   +1 more source